A share price of Ionis Pharmaceuticals Inc [IONS] is currently trading at $47.66, up 0.91%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IONS shares have gain 13.94% over the last week, with a monthly amount glided 30.75%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on June 14, 2024, when Bernstein upgraded its rating to a Mkt Perform but kept the price target unchanged to $44 for it. Previously, Wolfe Research upgraded its rating to Outperform on April 10, 2024, and kept the price target unchanged to $58. On January 02, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $62 on the stock. BofA Securities upgraded its rating to a Neutral and increased its price target to $52 on October 23, 2023. Raymond James initiated its recommendation with a Strong Buy and recommended $63 as its price target on September 29, 2023. Citigroup upgraded its rating to Buy for this stock on July 31, 2023, and upped its price target to $60.
Ionis Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $35.95 and $54.44. Currently, Wall Street analysts expect the stock to reach $48.75 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $47.66 at the most recent close of the market. An investor can expect a potential return of 2.29% based on the average IONS price forecast.
Analyzing the IONS fundamentals
Trailing Twelve Months sales for Ionis Pharmaceuticals Inc [NASDAQ:IONS] were 777.12M which represents -8.45% decline. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.5%, Pretax Profit Margin comes in at -0.47%, and Net Profit Margin reading is -0.49%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -1.08 and Total Capital is -0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 6.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.20 points at the first support level, and at 46.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 47.92, and for the 2nd resistance point, it is at 48.18.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ionis Pharmaceuticals Inc [NASDAQ:IONS] is 7.37. Further, the Quick Ratio stands at 7.28, while the Cash Ratio is 1.06. Considering the valuation of this stock, the price to sales ratio is 8.95, the price to book ratio is 23.44.
Transactions by insiders
Recent insider trading involved BERTHELSEN SPENCER R, Director, that happened on Jun 17 ’24 when 16000.0 shares were sold. Director, KLEIN JOSEPH III completed a deal on May 03 ’24 to sell 6000.0 shares. Meanwhile, EVP, Chief Business Officer Baroldi Joseph sold 4006.0 shares on Apr 16 ’24.
